site:www.pharmexec.com - Search Videos

What Challenges and Opportunities Are There in the Commercialization Space? | PharmExec

What Challenges and Opportunities Are There in the Commercializatio…

Overcoming the Challenges of AI Adoption | PharmExec

Overcoming the Challenges of AI Adoption | PharmExec

Creating Effective Peptide-Based Therapeutics | PharmExec

Creating Effective Peptide-Based Therapeutics | PharmExec

How Are Health Plans Impacting Drug Prices? | PharmExec

How Are Health Plans Impacting Drug Prices? | PharmExec

What Trends Are You Seeing in Pharma Commercialization? | PharmExec

What Trends Are You Seeing in Pharma Commercialization? | Pha…

The Importance of Data Strategy and Infrastructure in AI's Potential | PharmExec

The Importance of Data Strategy and Infrastructure in AI's Potential | Ph…

Setting Precedents for Rare Disease Therapies | PharmExec

Setting Precedents for Rare Disease Therapies | PharmExec

Preparing Health Systems for Looming DSCSA Enforcement | P…

How Long will it Take for the Market to be Impacted by FDA's ANDA Pri…

What Impact will DTC Programs have on Generic Drug Prices? | Ph…

What can Healthcare Manufacturing Learn from FDA's ANDA Prioritizat…

Influence of Pharmacologic Options on Clinical Practices | PharmExec

How are Updates to FDA's Processes Impacting Medical Affai…

Challenges of Positioning an Ultra-Sensitive Platform | PharmExec

How Will TrumpRx Impact Manufacturer-Produced DTC Prog…

How are Other Players in the Healthcare Industry Reacting to Dr…

Timing The Right Moment for Peptides to Lead Drug-Resistant P…

How Access to 25% of Benchmarking Data From Nationa…

Key Factors in Papzimeos' FDA Approval in Adults Patients with R…

The Secrets of Successful Drug Launches: The Six Root Causes o…

ClipNotes: AI Built for Pharma: Why Out-of-the-Box Beats Build-From-…

Asembia 2025: The Role of Face-to-Face Connection in Pharma Com…

The Challenges and Advantages of US Healthcare in a Worldwide Per…

Asembia 2025: Why AI Could Be the Key to Solving Access Challenge…

Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Tr…

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disea…

IMU-856 Shows Promise in Celiac Disease: Histologic Protection an…

What the Emrelis Approval Means for Pharma and Biotech ADC Strat…

How Pharma Can Effectively Combat Misinformation/Disinform…

AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple C…

See more videos